Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with non‐artemisinin treatment
It is very uncertain whether single dose primaquine at 0.75 mg/kg changes participants infectious at day 5 compared with no primaquine, with non‐artemisinin partner, (very low certainty).
2 findings from 1 review
Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
Cases of cholera ( · healthy children and adults, male and female; high risk population
2 findings from 1 review
Cases of severe dehydrating cholera ( · healthy children and adults, male and female; high risk population
2 findings from 1 review
Return to normal activities (days) · patients with benign gynaecological disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term outcomes · patients with benign gynaecological disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term complications (dichotomous) · patients with benign gynaecological disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intra‐operative visceral injury (dichotomous) · patients with benign gynaecological disease
It is very uncertain whether single‐port laparoscopic hysterectomy changes intra‐operative visceral injury (dichotomous) compared with laparoscopic hysterectomy (very low certainty).
1 finding from 1 review
Major short‐term complications (dichotomous) · patients with benign gynaecological disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with asthma not well controlled on ICS
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
1 finding from 1 review
Prevalence of delirium Not measured · people at risk of delirium in institutional long‐term care
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found